The Tumor Microenvironment Affects Circulating Tumor Cells Metastasis and the Efficacy of Immune Checkpoint Blockade in Non-small Cell Lung Cancer

被引:0
作者
Zhang, Xiuxiu [1 ]
Qiu, Sheng [1 ]
Wang, Cailian [1 ,2 ]
机构
[1] Southeast Univ, Sch Med, Nanjing 21009, Peoples R China
[2] Southeast Univ, Zhongda Hosp, Sch Med, Dept Oncol, Nanjing 21009, Peoples R China
关键词
Circulating tumor cells; tumor microenvironment; immune checkpoint blockade; non-small cell lung cancer; immunotherapy; chemotherapy; DNA METHYLATION; EXPRESSION; PROGNOSIS; CLUSTERS; OUTCOMES; PREDICT;
D O I
10.2174/1568009623666230503094337
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is one of the most lethal malignancies, with non-small cell lung cancer (NSCLC) being the most common histologic subtype. Metastasis leads to poor prognosis for patients with cancer. Tumor cells leave the tumor lesions, invade the surrounding stroma, and enter the bloodstream as circulating tumor cells (CTCs). The development of CTCs is the beginning of metastasis. The internal environment in which tumor cells grow and survive is called the tumor microenvironment (TME). It includes tumor cells, fibroblasts, immune cells, and the extracellular matrix. The TME is complex and dynamic. Moreover, the TME plays an important role in tumor development and metastasis and significantly impacts therapeutic outcomes. Immune checkpoint blockade (ICB) aims to inhibit the interaction of ligands with their corresponding receptors. ICB has the function of restoring the anti-tumor effect of immune cells. This review examines how TME interacts with CTCs, allowing CTCs to evade immunity and facilitating CTC metastasis. TME not only affects the progression of tumor metastasis but also interacts with tumor cells, which may affect the efficacy of immunotherapy.
引用
收藏
页码:2 / 13
页数:12
相关论文
共 96 条
[1]   Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis [J].
Aceto, Nicola ;
Bardia, Aditya ;
Miyamoto, David T. ;
Donaldson, Maria C. ;
Wittner, Ben S. ;
Spencer, Joel A. ;
Yu, Min ;
Pely, Adam ;
Engstrom, Amanda ;
Zhu, Huili ;
Brannigan, Brian W. ;
Kapur, Ravi ;
Stott, Shannon L. ;
Shioda, Toshi ;
Ramaswamy, Sridhar ;
Ting, David T. ;
Lin, Charles P. ;
Toner, Mehmet ;
Haber, Daniel A. ;
Maheswaran, Shyamala .
CELL, 2014, 158 (05) :1110-1122
[2]   Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].
Aguilar, E. J. ;
Ricciuti, B. ;
Gainor, J. F. ;
Kehl, K. L. ;
Kravets, S. ;
Dahlberg, S. ;
Nishino, M. ;
Sholl, L. M. ;
Adeni, A. ;
Subegdjo, S. ;
Khosrowjerdi, S. ;
Peterson, R. M. ;
Digumarthy, S. ;
Liu, C. ;
Sauter, J. ;
Rizvi, H. ;
Arbour, K. C. ;
Carter, B. W. ;
Heymach, J. V. ;
Altan, M. ;
Hellmann, M. D. ;
Awad, M. M. .
ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659
[3]   Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade [J].
Akbay, Esra A. ;
Koyama, Shohei ;
Liu, Yan ;
Dries, Ruben ;
Bufe, Lauren E. ;
Silkes, Michael ;
Alath, M. D. Maksudul ;
Magee, Dillon M. ;
Jones, Robert ;
Jinushi, Masahisa ;
Kulkarni, Meghana ;
Carretero, Julian ;
Wang, Xiaoen ;
Warner-Hatten, Tiquella ;
Cavanaugh, Jillian D. ;
Osa, Akio ;
Kumanogoh, Atsushi ;
Freeman, Gordon J. ;
Awad, Mark M. ;
Christiani, David C. ;
Bueno, Raphael ;
Hammerman, Peter S. ;
Dranoff, Glenn ;
Wong, Kwok-Kin .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (08) :1268-1279
[4]   The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer [J].
Alamgeer, Muhammad ;
Ganju, Vinod ;
Szczepny, Anette ;
Russell, Prudence A. ;
Prodanovic, Zdenka ;
Kumar, Beena ;
Wainer, Zoe ;
Brown, Tracey ;
Schneider-Kolsky, Michal ;
Conron, Matthew ;
Wright, Gavin ;
Watkins, D. Neil .
THORAX, 2013, 68 (12) :1095-1104
[5]   The lung microenvironment: an important regulator of tumour growth and metastasis [J].
Altorki, Nasser K. ;
Markowitz, Geoffrey J. ;
Gao, Dingcheng ;
Port, Jeffrey L. ;
Saxena, Ashish ;
Stiles, Brendon ;
McGraw, Timothy ;
Mittal, Vivek .
NATURE REVIEWS CANCER, 2019, 19 (01) :9-31
[6]   Minimal Residual Disease, Metastasis and Immunity [J].
Badia-Ramentol, Jordi ;
Linares, Jenniffer ;
Gomez-Llonin, Andrea ;
Calon, Alexandre .
BIOMOLECULES, 2021, 11 (02) :1-20
[7]   Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance [J].
Bagchi, Sreya ;
Yuan, Robert ;
Engleman, Edgar G. .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 :223-249
[8]   Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].
Bagley, Stephen J. ;
Kothari, Shawn ;
Aggarwal, Charu ;
Bauml, Joshua M. ;
Alley, Evan W. ;
Evans, Tracey L. ;
Kosteva, John A. ;
Ciunci, Christine A. ;
Gabriel, Peter E. ;
Thompson, Jeffrey C. ;
Stonehouse-Lee, Susan ;
Sherry, Victoria E. ;
Gilbert, Elizabeth ;
Eaby-Sandy, Beth ;
Mutale, Faith ;
DiLullo, Gloria ;
Cohen, Roger B. ;
Vachani, Anil ;
Langer, Corey J. .
LUNG CANCER, 2017, 106 :1-7
[9]   Understanding the tumor immune microenvironment (TIME) for effective therapy [J].
Binnewies, Mikhail ;
Roberts, Edward W. ;
Kersten, Kelly ;
Chan, Vincent ;
Fearon, Douglas F. ;
Merad, Miriam ;
Coussens, Lisa M. ;
Gabrilovich, Dmitry I. ;
Ostrand-Rosenberg, Suzanne ;
Hedrick, Catherine C. ;
Vonderheide, Robert H. ;
Pittet, Mikael J. ;
Jain, Rakesh K. ;
Zou, Weiping ;
Howcroft, T. Kevin ;
Woodhouse, Elisa C. ;
Weinberg, Robert A. ;
Krummel, Matthew F. .
NATURE MEDICINE, 2018, 24 (05) :541-550
[10]   PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review [J].
Brody, Robert ;
Zhang, Yiduo ;
Ballas, Marc ;
Siddiqui, Mohd Kashif ;
Gupta, Palvi ;
Barker, Craig ;
Midha, Anita ;
Walker, Jill .
LUNG CANCER, 2017, 112 :200-215